Upregulated ZO-1 correlates with favorable survival of gastrointestinal stromal tumor

Medical Oncology

Volumn 30, Issue 3, 2013, Pages

  Zhu, Huijun ^a   Lu, Juying ^a   Wang, Xudong ^a   Zhang, Huilin ^b   Tang, Xiaojun ^c   Zhu, Jin ^d   Mao, Yuan ^e  

^a NANTONG UNIVERSITY   (China)

^b WOMEN S HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^c NANJING MEDICAL UNIVERSITY   (China)

^d Huadong Medical Institute of Biotechniques   (China)

^e Jiangsu Provincial Hospital   (China)

Author keywords

GIST; Immunohistochemistry; Tumor marker; ZO 1

Indexed keywords

PROTEIN ZO1; TJP1 PROTEIN, HUMAN;

ADULT; ARTICLE; CANCER GRADING; CANCER LOCALIZATION; CANCER PATIENT; CANCER PROGNOSIS; CANCER SIZE; CANCER SURVIVAL; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TIGHT JUNCTION; TISSUE MICROARRAY; TUMOR INVASION; TUMOR SUPPRESSOR GENE; UPREGULATION; ADOLESCENT; AGED; GENETICS; MORTALITY; PATHOLOGY; PROGNOSIS; SURVIVAL; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; SURVIVAL ANALYSIS; UP-REGULATION; YOUNG ADULT; ZONULA OCCLUDENS-1 PROTEIN;

EID: 84879468219     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-013-0631-7     Document Type: Article

References (28)

1. Corless CL, Barnett CM, Heinrich MC. Gastrointestinal stromal tumours: origin and molecular oncology. Nat Rev Cancer. 2011;11:865-78.
2. Agaimy A. Gastrointestinal stromal tumors (GIST) from risk strati-fication systems to the new TNM proposal: more questions than answers? A review emphasizing the need for a standardized GIST reporting. Int J Clin Exp Pathol. 2010;3:461-71.
3. Liegl B, Hornick JL, Lazar AJ. Contemporary pathology of gastrointestinal stromal tumors. Hematol Oncol Clin North Am. 2009;23:49-68.
4. Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol. 2002;33:459-65.
5. Machairiotis N, Kougioumtzi I, Zarogoulidis P, et al. Gastrointestinal stromal tumor mesenchymal neoplasms: the offspring that choose the wrong path. J Multidiscip Healthc. 2013;6:127-31.
6. Kumar K, Rowsell C, Law C, et al. Coexistence of gastrointestinal stromal tumour and colorectal adenocarcinoma: two case reports. J Gastrointest Oncol. 2011;2:50-4.
7. Roberts PJ, Eisenberg B. Clinical presentation of gastrointestinal stromal tumors and treatment of operable disease. Eur J Cancer. 2002;38(Suppl 5):S37-8.
8. Hassan I, You YN, Shyyan R, et al. Surgically managed gastrointestinal stromal tumors: a comparative and prognostic analysis. Ann Surg Oncol. 2008;15:52-9.
9. Tuveson DA, Willis NA, Jacks T, et al. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene. 2001;20:5054-8.
10. Mol CD, Dougan DR, Schneider TR, et al. Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase. J Biol Chem. 2004;279:31655-63.
11. Rutkowski P, Debiec-Rychter M, Nowecki ZI, et al. Different factors are responsible for predicting relapses after primary tumors resection and for imatinib treatment outcomes in gastrointestinal stromal tumors. Med Sci Monit. 2007;13:CR515-22.
12. Rutkowski P, Nowecki ZI, Michej W, et al. Risk criteria and prognostic factors for predicting recurrences after resection of primary gastrointestinal stromal tumor. Ann Surg Oncol. 2007;14:2018-27.
13. Rutkowski P, Nowecki ZI, Debiec-Rychter M, et al. Predictive factors for long-term effects of imatinib therapy in patients with inoperable/metastatic CD117(+) gastrointestinal stromal tumors (GISTs). J Cancer Res Clin Oncol. 2007;133:589-97.
14. Chai Z, Goodenough DA, Paul DL. Cx50 requires an intact PDZbinding motif and ZO-1 for the formation of functional intercellular channels. Mol Biol Cell. 2011;22:4503-12.
15. Giri S, Poindexter KM, Sundar SN, et al. Arecoline induced disruption of expression and localization of the tight junctional protein ZO-1 is dependent on the HER 2 expression in human endometrial Ishikawa cells. BMC Cell Biol. 2010;11:53.
16. Nemeth Z, Szasz AM, Somoracz A, et al. Zonula occludens-1, occludin, and E-cadherin protein expression in biliary tract cancers. Pathol Oncol Res. 2009;15:533-9.
17. Martin TA, Watkins G, Mansel RE, et al. Loss of tight junction plaque molecules in breast cancer tissues is associated with a poor prognosis in patients with breast cancer. Eur J Cancer. 2004;40:2717-25.
18. Resnick MB, Gavilanez M, Newton E, et al. Claudin expression in gastric adenocarcinomas: a tissue microarray study with prognostic correlation. Hum Pathol. 2005;36:886-92.
19. Smalley KS, Brafford P, Haass NK, et al. Up-regulated expression of zonula occludens protein-1 in human melanoma associates with N-cadherin and contributes to invasion and adhesion. Am J Pathol. 2005;166:1541-54.
20. Huang J, Zhang J, Li H, et al. VCAM1 expression correlated with tumorigenesis and poor prognosis in high grade serous ovarian cancer. Am J Transl Res. 2013;5:336-46.
21. Mao Y, Zhang DW, Lin H, et al. Alpha B-crystallin is a new prognostic marker for laryngeal squamous cell carcinoma. J Exp Clin Cancer Res. 2012;31:101.
22. Karanikas M, Machairiotis N, Zarogoulidis P, et al. Non-Hodgkin lymphoma and GIST: molecular pathways and clinical expressions. Onco Targets Ther. 2012;5:433-8.
23. Tan CB, Zhi W, Shahzad G, et al. Gastrointestinal stromal tumors: a review of case reports, diagnosis, treatment, and future directions. ISRN Gastroenterol. 2012;2012:595968.
24. Andtbacka RH, Ng CS, Scaife CL, et al. Surgical resection of gastrointestinal stromal tumors after treatment with imatinib. Ann Surg Oncol. 2007;14:14-24.
25. Hwang I, An BS, Yang H, et al. Tissue-specific expression of occludin, zona occludens-1, and junction adhesion molecule A in the duodenum, ileum, colon, kidney, liver, lung, brain, and skeletal muscle of C57BL mice. J Physiol Pharmacol. 2013;64:11-8.
26. Gonzalez-Mariscal L, Lechuga S, Garay E. Role of tight junctions in cell proliferation and cancer. Prog Histochem Cytochem. 2007;42:1-57.
27. Martin TA, Jiang WG. Loss of tight junction barrier function and its role in cancer metastasis. Biochim Biophys Acta. 2009; 1788:872-91.
28. Tsukita S, Yamazaki Y, Katsuno T, et al. Tight junction-based epithelial microenvironment and cell proliferation. Oncogene. 2008;27:6930-8.